Atossa reports $79.5M cash, no debt; EVANGELINE Phase 2 40mg cohort shows 100% disease control rate

ATOSSA THERAPEUTICS, INC.

2024-Q2 EPS reported -$0.10

Ended Q2 2024 with $79.5M cash and cash equivalents, no debt; interest income $1.1M in Q2.
Total operating expenses $7.1M in Q2 2024 vs $7.8M in Q2 2023, down 9% YoY.
Phase 2 EVANGELINE 40mg cohort achieved 100% disease control rate at 24 weeks for ER+/HER2- breast cancer.
Completed enrollment in EVANGELINE 80mg PK run-in cohort and dosing in Phase 2 Karisma-Endoxifen trial (240 patients).
Appointed Heather Rees as CFO; joined Russell 3000 Index effective June 28, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.